Abstract
Introduction Cervical cancer (CC) arises as a result of chronic and persistent female genitalia infection by different oncogenic human papillomaviruses (HPV). The incidence of this disease is still high in developing countries such as Brazil, where the diagnosis is often made in advanced stages. HPV 16 is the most common type of CC worldwide. Studies concerning the association of different HPV 16 lineages with overall and disease-free CC survival rates can contribute to further understanding the behavior of different HPV 16 lineages concerning the prognosis of CC cases.
Objective Assess the CC prognosis of patients treated in a Brazilian institution with regard to HPV16 strains.
Methods Data were obtained from a prospective cohort of 334 CC patients recruited between July 2011 and March 2014 and treated at the Brazilian National Cancer Institute (INCA), in Rio de Janeiro, Brazil. HPV 16 lineages were identified in tumor tissue samples. Genetic HPV 16 diversity comprised 218 cases of lineage A, 10 of lineage B, 10 of lineage C and 96 of lineage D. In addition to HPV 16 lineages, age, histopathological type, staging, and treatment completion were evaluated regarding CC prognosis.
Results Median patient age was 48 years old. The most common histopathological type was squamous cell carcinoma (82.3%), followed by adenocarcinoma. Locally advanced disease staging was the most frequently detected, represented by similar stage II and III percentages (36.2% and 37.7%), followed by initial stage I (19.2%) and stage IV presenting distant disease (6.9%). Only 187 patients completed CC treatment. Age, histological type, staging, and treatment completion were associated with a higher risk of death, which was not observed for the HPV 16 lineage variable. With regard to age, each one year of life increase led to about a 1% increase in risk of death. Other histopathological types (poorly differentiated carcinoma, adenosquamous, neuroendocrine and sarcoma) were associated with a higher risk of death compared to adenocarcinoma. Squamous cell carcinoma also represented a higher risk of death compared to adenocarcinoma, albeit non-statistically significant. Patients diagnosed in advanced stages exhibited a higher risk of death, and those who did not complete treatment exhibited an over 2-fold increased risk of death.
Conclusion This study found no associations between HPV 16 lineages A, B, C and D and CC prognosis.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
"N/A"
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Name of the ethics commitee: National Cancer Institute Ethics Committee Approval number: 53398416.0.0000.5274 Form of consent obtained: written
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Our data sets will be available upon request. Data are available from the Ethics Committee (contact via +552132074550) for researchers who meet the criteria for access to confidential data.
